Safety of eribulin: A real-world study based on a pharmacovigilance database
Yao Zhou, Jie Gong, Lele Shen, Jie Ling, Shiting Wu, Anqi Ge, Lin Qi, Lifang Liu · 2026
Read Safety of eribulin: A real-world study based on a pharmacovigilance database by Yao Zhou, Jie Gong, Lele Shen, Jie Ling, Shiting Wu, Anqi Ge, Lin Qi, Lifang Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356800.txt.
Description
Yao Zhou led a team of eight authors who checked the real-world safety of a cancer drug called eribulin, published in PLOS ONE in 2026. The drug is used for advanced breast cancer. Trials before approval enroll selected patients, so safety in everyday care can look different once many more people receive the drug.
Zhou's team mined a large database of adverse event reports from routine practice. The signals they found either support what trials showed or raise new points for doctors to watch. Oncologists weighing this drug for a frail patient gain a fuller picture of its risks. Real-world checks like this are now a standard part of judging any cancer drug.
Catalog record
| CREATOR | Yao Zhou, Jie Gong, Lele Shen, Jie Ling, Shiting Wu, Anqi Ge, Lin Qi, Lifang Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35252 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |